The European Society of Cardiology updated its treatment guidelines for ventricular arrhythmia patients to include subcutaneous implantable cardioverter defibrillators. The announcement was made at the society’s annual meeting in London on Saturday. The new guidelines recommend the use of the S-ICD units as a possible alternative to transvenous defibrillators in patients with an ICD indication […]
Medtronic’s renal denervation no better at 1 year, researchers say
St. Jude cries victory with its quadripolar leads
Medical device giant St. Jude Medical (NYSE:STJ) had high praise for its own quadripolar leads, saying that blow away any competition from older bipolar leads.
Bluegrass Vascular taps ex-ArthoCare R&D chief Niederauer for CEO | Personnel Moves
Bluegrass Vascular Technologies said it named Gabriele Niederauer its new president & CEO, hard on the heels of a Series A funding round that brought in $4.5 million for its Surfacer central venous catheter.
Study: Remotely monitored heart patients live longer
Heart failure patients with implant-based remote monitoring die less frequently from any cause, according to Biotronik study results released at the European Society of Cardiology congress in Amsterdam.
TAVI: Edwards Lifesciences’ Sapien valve safe for redos, may lower diabetic death toll
ESC 2013: Pacemakers set life expectancy back to normal, researchers say
A slow heart rhythm puts patients at risk of early death, but a cardiac implant may help reset those odds, according to a Dutch study presented this week at the European Society of Cardiology Congress in Amsterdam.
A study of pacemakers in 23 Dutch hospitals found that devices implanted to treat slow heart rhythm helped restore normal life expectancy.
ESC 2013: Medtronic’s Symplicity hypertension treatment still promising at 1 and 3 years
New data on Medtronic’s (NYSE:MDT) Symplicity renal denervation system showed the device is safe and effective at 1 and 3 years, the company announced this week.
ESC 2012 Roundup: New heart care guidelines, TAVI studies and more
Women vs. men: Gender-based research at ESC 2012
Shock study calls into question decades of intra-aortic balloon counter-pulsation
Physicians and medical boards may have to reconsider decades of cardiogenic shock treatment after the highly anticipated IABP-Shock study found no significant benefit in using intra-aortic balloon pump therapy in heart attack patients.
MassDevice Network
@MassDevice
LinkedIn
YouTube